Vulnerabilities in mIDH2 AML confer sensitivity to APL-like targeted combination therapy

Area of Science:

• Hematology
• Oncology
• Molecular Biology

Background:

• Targeted therapies for human leukemia show efficacy but often face resistance.
• Isocitrate dehydrogenase (IDH) mutations occur in approximately 20% of acute myeloid leukemia (AML) cases, with targeted therapies under development.
• Understanding leukemia evolution and identifying persistent vulnerabilities is crucial for overcoming resistance.

Purpose of the Study:

• To characterize the evolution of leukemia from mutant IDH2 (mIDH2)-dependence to independence.
• To identify targetable vulnerabilities in mIDH2 leukemia that persist throughout disease progression.
• To explore novel therapeutic strategies for mIDH2-mutated AML.

Main Methods:

• Characterization of leukemia evolution from mIDH2-dependent to independent states.
• Mechanistic investigation of oxidative stress, 1-carbon metabolism, and glutathione levels.
• Analysis of LSD1 inhibition, PIN1 levels, and all-trans retinoic acid (ATRA) signaling.
• Assessment of therapeutic efficacy using mouse and human mIDH1/2 leukemic models.

Main Results:

• mIDH2 leukemia exhibits metastable vulnerabilities related to oxidative/genotoxic stress and suppressed ATRA signaling.
• Increased 1-carbon metabolism and glutathione levels do not fully mitigate stress in mIDH2 leukemia.
• Inhibition of LSD1 and increased PIN1 levels contribute to suppressed ATRA signaling.
• The combination of ATRA and arsenic trioxide (ATO) demonstrates powerful synergy and efficacy in preclinical models.

Conclusions:

• mIDH2 leukemia harbors distinct vulnerabilities at the GSH/ROS and PIN1/LSD1 nodes.
• The combination of ATRA and ATO effectively targets these vulnerabilities, showing significant therapeutic potential.
• Findings support the development of targeted, APL-like combinatorial therapies for IDH-mutated AML.